Moleculin Biotech Stock Shares Owned By Institutions
| MBRX Stock | USD 1.05 0.02 1.87% |
Moleculin Biotech fundamentals help investors to digest information that contributes to Moleculin Biotech's financial success or failures. It also enables traders to predict the movement of Moleculin Stock. The fundamental analysis module provides a way to measure Moleculin Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Moleculin Biotech stock.
Moleculin | Shares Owned By Institutions |
Moleculin Biotech Company Shares Owned By Institutions Analysis
Moleculin Biotech's Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current Moleculin Biotech Shares Owned By Institutions | 3.49 % |
Most of Moleculin Biotech's fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Moleculin Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Moleculin Shares Owned By Institutions Driver Correlations
Understanding the fundamental principles of building solid financial models for Moleculin Biotech is extremely important. It helps to project a fair market value of Moleculin Stock properly, considering its historical fundamentals such as Shares Owned By Institutions. Since Moleculin Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Moleculin Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Moleculin Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 3.493% of Moleculin Biotech are shares owned by institutions. This is 92.18% lower than that of the Biotechnology sector and 92.65% lower than that of the Health Care industry. The shares owned by institutions for all United States stocks is 91.09% higher than that of the company.
Moleculin Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Moleculin Biotech's direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Moleculin Biotech could also be used in its relative valuation, which is a method of valuing Moleculin Biotech by comparing valuation metrics of similar companies.Moleculin Biotech is currently under evaluation in shares owned by institutions category among its peers.
Moleculin Fundamentals
| Return On Equity | -1.41 | ||||
| Return On Asset | -0.57 | ||||
| Current Valuation | 10.43 M | ||||
| Shares Outstanding | 13.3 M | ||||
| Shares Owned By Insiders | 0.75 % | ||||
| Shares Owned By Institutions | 3.49 % | ||||
| Number Of Shares Shorted | 2.2 M | ||||
| Price To Earning | (3.81) X | ||||
| Price To Book | 2.38 X | ||||
| EBITDA | (26.52 M) | ||||
| Net Income | (21.76 M) | ||||
| Cash And Equivalents | 58 M | ||||
| Cash Per Share | 2.03 X | ||||
| Total Debt | 358 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 10.47 X | ||||
| Book Value Per Share | 2.49 X | ||||
| Cash Flow From Operations | (23.86 M) | ||||
| Short Ratio | 0.08 X | ||||
| Earnings Per Share | (12.04) X | ||||
| Target Price | 18.0 | ||||
| Number Of Employees | 18 | ||||
| Beta | 1.94 | ||||
| Market Capitalization | 14.5 M | ||||
| Total Asset | 16.93 M | ||||
| Retained Earnings | (153.37 M) | ||||
| Working Capital | (165 K) | ||||
| Current Asset | 28.09 K | ||||
| Current Liabilities | 772.79 K | ||||
| Net Asset | 16.93 M |
About Moleculin Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Moleculin Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Moleculin Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Moleculin Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Moleculin Stock Analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.